

HR 417

Medical Innovation Prize Act of 2005

Congress: 109 (2005–2007, Ended)

Chamber: House

Policy Area: Health

Introduced: Jan 26, 2005

Current Status: Referred to the Subcommittee on Courts, the Internet, and Intellectual Property.

Latest Action: Referred to the Subcommittee on Courts, the Internet, and Intellectual Property. (Mar 2, 2005)

Official Text: <https://www.congress.gov/bill/109th-congress/house-bill/417>

Sponsor

Name: Rep. Sanders, Bernard [I-VT-At Large]

Party: Independent • **State:** VT • **Chamber:** Senate

Cosponsors

No cosponsors are listed for this bill.

Committee Activity

Committee	Chamber	Activity	Date
Energy and Commerce Committee	House	Referred to	Feb 25, 2005
Judiciary Committee	House	Referred to	Mar 3, 2005

Subjects & Policy Tags

Policy Area:

Health

Related Bills

No related bills are listed.

Medical Innovation Prize Act of 2005 - Prohibits any person from having the right to exclusively manufacture, distribute, sell, or use a drug, a biological product, or a manufacturing process for a drug or biological product in interstate commerce, notwithstanding current Federal laws providing otherwise, including laws governing patent rights or exclusive marketing periods.

Establishes the Fund for Medical Innovation Prizes. Requires the Board of Trustees for the Fund to award prize payments for medical innovations relating to a drug, biological product, or manufacturing process for a drug or biological product. Requires an eligible award recipient to be either the first person to receive market clearance or the holder of the patent. Directs the Board to consider: (1) the number of patients who benefited from the drug, including non-U.S. patients; (2) the incremental therapeutic benefit of the drug to treat the same disease or condition; (3) the degree to which the drug addresses priority health care needs, such as global infectious diseases and neglected diseases that primarily afflict the poor in developing countries; and (4) the improved efficiency of manufacturing processes for drugs or biological processes. Allows the Board to award prize payments for no more than ten years. Allocates certain minimum payments from the Fund for priority research and development.

Requires the Comptroller General to conduct an audit to determine the Board's effectiveness in bringing to market new drugs, vaccines, biological products, and manufacturing processes in a cost-effective manner and addressing society's global medical needs.

Actions Timeline

- **Mar 2, 2005:** Referred to the Subcommittee on Courts, the Internet, and Intellectual Property.
- **Feb 25, 2005:** Referred to the Subcommittee on Health.
- **Feb 2, 2005:** Sponsor introductory remarks on measure. (CR E149)
- **Jan 26, 2005:** Introduced in House
- **Jan 26, 2005:** Introduced in House
- **Jan 26, 2005:** Sponsor introductory remarks on measure. (CR E130-131)
- **Jan 26, 2005:** Referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
- **Jan 26, 2005:** Referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
- **Jan 26, 2005:** Referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.